Clinical Trials Logo

Filter by:
  • No longer available  
  • Page 1 ·  Next »
NCT ID: NCT00063791 No longer available - Multiple Myeloma Clinical Trials

A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Start date: n/a
Phase: Phase 2
Study type: Expanded Access

The purpose of this study is to give patients who have had 4 or more prior lines of therapy for multiple myeloma access to VELCADE. The study is for patients who are not eligible for other clinical trials with VELCADE and for who VELCADE would otherwise not be available.

NCT ID: NCT00071708 No longer available - Clinical trials for Major Depressive Disorder

Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is not available.

NCT ID: NCT00210665 No longer available - Sarcoma Clinical Trials

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Start date: n/a
Phase: Phase 3
Study type: Expanded Access

The purpose of this study is to facilitate access to trabectedin for eligible previously treated patients with soft tissue sarcoma (STS), who cannot be expected to benefit from currently available therapeutic options but who may benefit from treatment with trabectedin. The safety profile of trabectedin will be evaluated to further assess the potential risks of trabectedin treatment.

NCT ID: NCT00419367 No longer available - Clinical trials for Lymphoma, T-Cell, Cutaneous

Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)

Start date: n/a
Phase: N/A
Study type: Expanded Access

In an effort to allow patients continued access to vorinostat outside of the base study, patients that are actively receiving study medication will discontinue from this study and receive vorinostat via another method supported by the SPONSOR (e.g. Named Patient Program (NPP)). For those institutions that do not allow receipt of an investigational therapy outside of a clinical trial, patients that are actively receiving study medication and continue to meet eligibility will transition to an extension phase of the study and the base study will be closed. The extension phase will begin as soon as the protocol amendment is implemented.

NCT ID: NCT00495066 No longer available - Melanoma Clinical Trials

Compassionate Use Trial for Unresectable Melanoma With Ipilimumab

Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of the study is to provide treatment with Ipilimumab to subjects who have serious or immediately life-threatening unresectable Stage III or Stage IV melanoma, who have no alternative treatment options, and whose physicians believe, based upon available data on benefit and risk, that it is appropriate to administer Ipilimumab at a dose of 3 mg/kg induction (with re-induction, if eligible), or for eligible subjects previously enrolled in Ipilimumab studies CA184-042, CA184-078, CA184-087, MDX010-16, or MDX010-20.

NCT ID: NCT00511771 No longer available - Clinical trials for Chronic Idiopathic Constipation

A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation

Start date: n/a
Phase: N/A
Study type: Expanded Access

To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available treatment(s) and / or patients who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.

NCT ID: NCT00517894 No longer available - Lymphoma Clinical Trials

Dose-Dense Therapy in Aggressive Lymphoma

Start date: n/a
Phase: N/A
Study type: Expanded Access

To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.

NCT ID: NCT00535080 No longer available - Clinical trials for Basal Cell Carcinoma

Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease

Start date: n/a
Phase: N/A
Study type: Expanded Access

The aim of this study is to provide this investigational drug to patients who cannot be optimally treated with conventional therapies and to collect efficacy and safety data on the use of Metvix PDT in subjects with field actinic keratoses, large/multiple superficial basal cell carcinomas (BCCs) or Bowen's disease.

NCT ID: NCT00583505 No longer available - Defects Clinical Trials

Emergency/Compassionate Use - Membranous VSD Occluder

Start date: n/a
Phase: N/A
Study type: Expanded Access

Emergency/Compassionate use of the AMPLATZER Membranous VSD Occluder

NCT ID: NCT00583583 No longer available - Ductus Clinical Trials

Emergency/Compassionate Use - AMPLATZER Duct Occluder

Start date: n/a
Phase: N/A
Study type: Expanded Access

Emergency/compassionate use for the AMPLATZER Duct Occluder